Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07104091 phase 1/2a dose escalation and expansion in advanced solid tumors
2024-515492-34-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of tegtociclib in breast cancer, ovarian cancer, small cell lung cancer (SCLC) and 4 more (6 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 4 more. Planned start Mar 2023; status: authorised.
02
Drugs
tegtociclib
03
Conditions
breast cancerovarian cancersmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-515492-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515492-34-00.